Development of Vitiligo in Patients Treated With BRAF/MEK Inhibitors: A Systematic Review

Abstract

Keywords

systematic review BRAF inhibitor MEK inhibitor vitiligo safety

Get full access to this article

View all access options for this article.

References

Muñoz-Couselo

García

Pérez-García

Cebrián

Castán

. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med. 2015;3(15):207.

Wilmott

Long

Howle

, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386-1394.

Peiffer

Farahpour

Sriram

, et al. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes. Cancer Immunol Immunother. 2021;70(6):1635-1647.

Maio

. Melanoma as a model tumour for immuno-oncology. Ann Oncol. 2012;23(suppl 8):viii10-viii14.

Byrne

Turk

. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684-694.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB